Advisory Council for the Elimination of Tuberculosis Meeting (ACET), 33316 [2010-14076]
Download as PDF
<![CDATA[
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
33316
Federal Register / Vol. 75, No. 112 / Friday, June 11, 2010 / Notices
The docket number is FDA–2010–N–
0268. The docket will be open for public
comment on June 11, 2010. The docket
will close on December 3, 2010.
Interested persons are encouraged to use
the docket to submit either electronic or
written comments regarding this
meeting. Submit electronic comments to
https://www.regulations.gov. Submit
written comments to the Division of
Dockets Management, Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. It is only
necessary to send one set of comments.
It is no longer necessary to send two
copies of mailed comments. Identify
comments with the docket number
found in brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Agenda: On December 14 and 15,
2010, the committee will discuss and
make recommendations on scientific
issues raised in petitions received by
FDA concerning the final rule on the
classification of dental amalgam, which
published in the Federal Register on
August 4, 2009 (74 FR 38686). These
petitions (docket numbers FDA–2008–
N–0163 and FDA–2009–P–0357) can be
viewed at https://www.regulations.gov/
search/Regs/home.html#
documentDetail?R=09000064809fbe3f;
https://www.regulations.gov/search/
Regs/home.html#documentDetail?
R=0900006480a1d1bc; https://
www.regulations.gov/search/Regs/
home.html#documentDetail?
R=0900006480a24048; and https://
www.regulations.gov/search/Regs/
home.html#documentDetail?
R=0900006480a80ae5. Issues raised in
the petitions include the adequacy of
the risk assessment performed by FDA
in classifying dental amalgam in light of
a new report on risk assessments issued
by the National Academy of Sciences,
entitled ‘‘Science and Decisions:
Advancing Risk Assessment,’’ NAP,
2009.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
VerDate Mar<15>2010
15:04 Jun 10, 2010
Jkt 220001
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before December 6, 2010.
Oral presentations from the public will
be scheduled at 1 p.m. on December 14,
2010 and at 8 a.m. on December 15,
2010. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 29, 2010. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
December 1, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams, Conference Management
Staff, 301–796–5966, at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 8, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–14084 Filed 6–10–10; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Council for the Elimination of
Tuberculosis Meeting (ACET)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned council:
Times and Dates: 8:30 a.m.–5:30 p.m., June
29, 2010. 8:30 a.m.–2:30 p.m., June 30, 2010.
Place: Corporate Square, Building 8, 1st
Floor Conference Room, Atlanta, Georgia
30333, telephone (404) 639–8317.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This council advises and makes
recommendations to the Secretary of Health
and Human Services, the Assistant Secretary
for Health, and the Director, CDC, regarding
the elimination of tuberculosis. Specifically,
the Council makes recommendations
regarding policies, strategies, objectives, and
priorities; addresses the development and
application of new technologies; and reviews
the extent to which progress has been made
toward eliminating tuberculosis.
Matters To Be Discussed: Agenda items
include: Issues pertaining to pediatric
tuberculosis; modernizing tuberculosis
control; foreign born guidelines update; the
affordable care act and public health; STOP
TB USA report update; and other related
tuberculosis issues.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Margie Scott-Cseh, CDC, 1600 Clifton Road,
NE., M/S E–07, Atlanta, Georgia 30333,
telephone (404) 639–8317. The Director,
Management Analysis and Services Office,
has been delegated the authority to sign
Federal Register Notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: June 4, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–14076 Filed 6–10–10; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4160–01–S
PO 00000
Frm 00079
Fmt 4703
Sfmt 9990
E:\FR\FM\11JNN1.SGM
11JNN1
]]>Agencies
[Federal Register Volume 75, Number 112 (Friday, June 11, 2010)]
[Notices]
[Page 33316]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-14076]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Council for the Elimination of Tuberculosis Meeting
(ACET)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
council:
Times and Dates: 8:30 a.m.-5:30 p.m., June 29, 2010. 8:30 a.m.-
2:30 p.m., June 30, 2010.
Place: Corporate Square, Building 8, 1st Floor Conference Room,
Atlanta, Georgia 30333, telephone (404) 639-8317.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This council advises and makes recommendations to the
Secretary of Health and Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the elimination of
tuberculosis. Specifically, the Council makes recommendations
regarding policies, strategies, objectives, and priorities;
addresses the development and application of new technologies; and
reviews the extent to which progress has been made toward
eliminating tuberculosis.
Matters To Be Discussed: Agenda items include: Issues pertaining
to pediatric tuberculosis; modernizing tuberculosis control; foreign
born guidelines update; the affordable care act and public health;
STOP TB USA report update; and other related tuberculosis issues.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Margie Scott-Cseh, CDC,
1600 Clifton Road, NE., M/S E-07, Atlanta, Georgia 30333, telephone
(404) 639-8317. The Director, Management Analysis and Services
Office, has been delegated the authority to sign Federal Register
Notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Dated: June 4, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2010-14076 Filed 6-10-10; 8:45 am]
BILLING CODE 4163-18-P
